Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of amlitelimab monotherapy in adults with severe alopecia areata
jRCT2061240031Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of amlitelimab in alopecia areata (3 arms), sponsored by Sanofi. Primary endpoint: Change from baseline in Severity of Alopecia Tool score at Week 36. Started Jul 2024; status: active, not recruiting.
02
Drugs
amlitelimab
03
Conditions
alopecia areata
Beyond the preview
Go deeper on jRCT2061240031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240031.